FDA Formally Rescinds Laboratory-Developed Tests Final Rule

FDA Formally Rescinds Laboratory-Developed Tests Final Rule

The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.

The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.

Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.

Sources:

https://www.reginfo.gov/public/do/eoDetails?rrid=1044563

https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf

https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3

A logo with the letters 'HD' for 'HealthDay'

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

PATIENT AI Act Discussion Draft, AMA Issue Brief for Clinical AI Liability Released

Accountability and reimbursement for artificial intelligence (AI)-based technologies were highlighted topics of discussion last week.

Read More
TELCOR Promotions - November 2026

TELCOR Promotions - November 2026

Lincoln, NE – November 2026 TELCOR is proud to announce the promotion of Stephanie Gonnerman to Senior Analyst, Revenue Cycle Management (RCM).

Read More
Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

Recently Released CLFS Data Reveal Large Differences in Test Volume by Laboratory Setting

The Centers for Medicare and Medicaid Services (CMS) released a report on Oct. 20 detailing significant differences in the share of reported test...

Read More